Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-28T06:34:38.879Z Has data issue: false hasContentIssue false

Chapter 17 - Pharmacological Therapy

Published online by Cambridge University Press:  15 March 2024

By
Chike I. Okocha  and
Jules Haste
Edited by
Roland Dix ,
Stephen Dye  and
Stephen M. Pereira
Roland Dix
Affiliation:
Gloucestershire Health and Care NHS Foundation Trust, Gloucester
Stephen Dye
Affiliation:
Norfolk and Suffolk Foundation Trust, Ipswich
Stephen M. Pereira
Affiliation:
Keats House, London
Get access

Summary

Almost all patients admitted to psychiatric intensive care units receive pharmacological interventions and medications are often the major treatment intervention. PICU professional staff need to ensure that medication is used safely. This chapter discusses the common medication used in PCUs, their history, evidence base and adverse effects.

Keywords

adherenceadverse effectshigh-dose antipsychoticslong-acting injections (LAIs)maintenancemonitoringmood stabiliserspharmacologypsychosis
Type
Chapter
Information
Psychiatric Intensive Care , pp. 216 - 229
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Assion, HJ, Reinbold, H, Lemanski, S, Basilowski, M and Juckel, G (2008) Amisulpride Augmentation in Patients with Schizophrenia Partially Responsive or Unresponsive to Clozapine. A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry 41 (1) 24–8.CrossRefGoogle ScholarPubMed
Atkin, K, Kendall, F and Gould, D (1996) Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland. British Journal of Psychiatry 169 (4) 483–8.CrossRefGoogle ScholarPubMed
Baastrup, PC, Paulsen, JC, Schou, M, Thomsen, K and Amidsen, A (1970) Prophylactic Lithium: Double-Blind Discontinuation in Manic-Depressive and Recurrent Depressive Disorders. Lancet 2 (7668) 326–30.Google ScholarPubMed
Baldwin, DS, Anderson, IM, Nutt, DJ, Allgulander, C, Bandelow, B, den Boer, JA, et al. (2014) Evidence-Based Pharmacological Treatment of Anxiety Disorders, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder: A Revision of the 2005 Guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology 28 (5) 403–39.CrossRefGoogle ScholarPubMed
Barnes, TR, Drake, R, Paton, C, Cooper, SJ, Deakin, B, Ferrier, IN, et al. (2020) Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia: Updated Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 34 (1) 3–78.CrossRefGoogle ScholarPubMed
Beasley, Jr, CM Hamilton, SH and Crawford, AM (1997) Olanzapine versus Haloperidol: Acute Phase Results of the International Double-Blind Olanzapine Trial. European Neuropsychopharmacology 7 (2) 125–37.CrossRefGoogle ScholarPubMed
Beasley, Jr, CM, Sanger, T, and Satterlee, W (1996b) Olanzapine versus Placebo: Results of a Double-Blind, Fixed-Dose Olanzapine Trial. Psychopharmacology 124 (1–2) 159–67.CrossRefGoogle ScholarPubMed
Beasley, Jr, CM, Tollefson, G and Tran, P (1996a) Olanzapine versus Placebo and Haloperidol: Acute Phase Results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology 14 (2) 111–23.CrossRefGoogle ScholarPubMed
Bellack, AS and Mueser, KT (1993) Psychosocial Treatment for Schizophrenia. Schizophrenia Bulletin 19 (2) 317–36.CrossRefGoogle ScholarPubMed
Boter, H, Peuskens, J, Libiger, J, Fleischhacker, WW, Davidson, M, Galderisi, S, et al. (2009) Effectiveness of Antipsychotics in First Episode Schizophrenia and Schizophreniform Disorder on Response and Remission: An Open Randomized Clinical Trial (EUFEST). Schizophrenia Research 115 (1–2) 97–103.CrossRefGoogle ScholarPubMed
Boyer, P, Lecrucibier, Y and Puech, AJ (1995) Treatment of Negative Symptoms of Schizophrenia with Amisulpride. British Journal of Psychiatry 166 (1) 68–72.CrossRefGoogle ScholarPubMed
Britannia (2020) Summary of Product Characteristics – Denzapine 100 mg tablets (clozapine). Reading: Britannia Pharmaceuticals Ltd. www.medicines.org.uk/emc/product/6120/smpc.Google Scholar
Cardoni, AA (1995) Risperidone: Review and Assessment of Its Role in the Treatment of Schizophrenia. Annals of Pharmacotherapy 29 (6) 610–18.CrossRefGoogle ScholarPubMed
Carter, RM, Wittchen, HU, Pfister, H and Kessler, RC (2001) One-Year Prevalence of Subthreshold and Threshold DSM-IV Generalized Anxiety Disorder in a Nationally Representative Sample. Depression and Anxiety 13 (2) 78–88.CrossRefGoogle Scholar
Castelao, JF, Ferrerira, L, Gelders, YG and Heylen, SLE (1989) The Efficacy of the D2 and 5HT2 Antagonist Risperidone in the Treatment of Chronic Psychoses. An Open Dose Finding Study. Schizophrenia Research 2 (4–5) 411–15.CrossRefGoogle ScholarPubMed
Chouinard, G, Jones, B and Remington, G (1993) A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients. Journal of Clinical Psychopharmacology 13 (1) 35–40.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, TA, Salanti, G, Geddes, JR, Higgins, JP, Churchill, R, et al. (2009) Comparative Efficacy and Acceptability of 12 New-Generation Antidepressants: A Multiple Treatments Meta-Analysis. Lancet 373 (9665) 746–58.CrossRefGoogle ScholarPubMed
Citrome, L, Cucchiaro, J, Sarma, K, Phillips, D, Silva, R, Tsuchiya, S, et al. (2012) Long-Term Safety and Tolerability of Lurasidone in Schizophrenia: A 12-Month, Double-Blind, Active-Controlled study. International Clinical Psychopharmacology 27 (3) 165–76.CrossRefGoogle ScholarPubMed
Claus, A, Bollen, J and de Cuyper, H (1992) Risperidone versus Haloperidol in the Treatment of Chronic Schizophrenic Inpatient: A Multi-Centre Double-Blind Comparative Study. Acta Psychiatrica Scandanavia 85 (4) 295–305.CrossRefGoogle Scholar
Cleare, A, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, et al. (2015) Evidence-Based Guidelines for Treating Depressive Disorders with Antidepressants: A Revision of the 2008 British Association for Psychopharmacology Guidelines. Journal of Psychopharmacology 29 (5) 459–525.CrossRefGoogle ScholarPubMed
Cooper, SJ, Reynolds, GP, Barnes, TRE, England, E, Haddad, PM, Heald, A, et al. (2016) BAP Guidelines on the Management of Weight Gain and Metabolic Disturbances and Cardiovascular Risk Associated with Psychosis and Antipsychotic Drug Treatment. Journal of Psychopharmacology 30 (8) 717–48.CrossRefGoogle ScholarPubMed
Cooper, T (1996) Clozapine Plasma Level Monitoring: Current Status. Psychiatric Quarterly 67 (4) 297–311.CrossRefGoogle ScholarPubMed
Coppen, A, Noguera, R and Bailey, J (1971) Prophylactic Lithium in Affective Disorders: A Controlled Trial. Lancet 2 (7719) 275–9.Google Scholar
Correll, CU (2010) From Receptor Pharmacology to Improved Outcomes: Individualising the Selection, Dosing, and Switching of Antipsychotics. European Psychiatry 25 (Suppl 2) S12–21.CrossRefGoogle ScholarPubMed
Daniel, DG and Whitcomb, SR (1998) Treatment of the Refractory Schizophrenic Patient. Journal of Clinical Psychiatry 59 (Suppl 1) 13–19.Google ScholarPubMed
Davidson, M, Emsley, R, Kramer, M, Ford, L, Pan, G, Lim, P, et al (2007) Efficacy, Safety, and Early Response of Paliperidone Extended-Release Tablets (Paliperidone ER): Results of a 6-Week, Randomised, Placebo-Controlled Study. Schizophrenia Research 93 (1–3) 117–30.CrossRefGoogle Scholar
Day, JC, Wood, G, Dewey, M and Bentall, RP (1995) A Self-Rating Scale for Measuring Neuroleptic Side-Effects: Validation in a Group of Schizophrenic Patients. British Journal of Psychiatry 166 (5) 650–3.CrossRefGoogle Scholar
Department of Health (2015) Mental Health Act 1983: Code of Practice. London: TSO.Google Scholar
Devinsky, O, Honigfield, G and Patin, J (1991) Clozapine-Related Seizures. Neurology 41 (3) 369–71.CrossRefGoogle ScholarPubMed
Durgam, S, Earley, W, Lipschitz, A, Guo, H, Laszlovszky, I, Nemeth, G, et al. (2016) An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients with Bipolar I Depression. American Journal of Psychiatry 173 (3) 271–81.CrossRefGoogle ScholarPubMed
Durgam, S, Starace, A, Li, D, Migliore, R, Ruth, A, Nemeth, G, et al (2015) The Efficacy and Tolerability of Cariprazine in Acute Mania Associated with Bipolar I Disorder: A Phase II Trial. Bipolar Disorder 17 (1) 63–75.CrossRefGoogle ScholarPubMed
Emrich, HM, Dose, M and von Serssen, D (1985) The Use of Sodium Valproate and Oxcarbazepine in Patients with Affective Disorders. Journal of Affective Disorders 8 (3) 243–50.CrossRefGoogle ScholarPubMed
Esteves, P, Mota, D, Cerejeira, J and Mendes, F (2015). Low Doses of Adjunctive Aripiprazole as Treatment for Antipsychotic-induced Hyperprolactinemia: a Literature Review. European Psychiatry 30 (Suppl 1) 393.CrossRefGoogle Scholar
Fieve, RR, Kumbaraci, T and Dunner, DL (1976) Lithium Prophylaxis of Depression in Bipolar I, Bipolar II, and Unipolar Patients. American Journal of Psychiatry 133 (8) 925–30.Google ScholarPubMed
Freeman, TW, Clothier, JL, Passaglia, P and Lesem, MD (1992) A Double-Blind Comparison of VPA and LI in the Treatment of Acute Mania. American Journal of Psychiatry 149 (1) 108–11.Google Scholar
Garnock-Jones, KP (2017) Cariprazine: A Review in Schizophrenia. CNS Drugs 31 (6) 513–25.CrossRefGoogle ScholarPubMed
Geddes, JR, Goodwin, GM, Rendell, J, Azorin, JM, Cipriani, A, Ostacher, MJ, et al. (2010) Lithium Plus Valproate Combination Therapy Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE): A Randomized Open-Label Trial. Lancet 375 (9712) 385–95.Google Scholar
Gillespie, AL, Samanaite, R, Mill, J, Egerton, A and MacCabe, JH (2017) Is Treatment-Resistant Schizophrenia Categorically Distinct from Treatment-Responsive Schizophrenia? A Systematic Review. BMC Psychiatry 17 (1) 12.CrossRefGoogle ScholarPubMed
GlaxoSmithKline UK (2021) Summary of Product Characteristics – Lamictal Tablets (Lamotrigine). Middlesex; GlaxoSmithKline UK. www.medicines.org.uk/emc/product/8052/smpc.Google Scholar
Goodnick, PJ and Jerry, JM (2002) Aripiprazole: Profile on Efficacy and Safety. Expert Opinion on Pharmacotherapy 3 (12) 1773–81.CrossRefGoogle ScholarPubMed
Goodwin, GM, Haddad, PM, Ferrier, IN, Aronson, JK, Barnes, TRE, Cipriani, A, et al. (2016) Evidence-Based Guidelines for Treating Bipolar Disorder: Revised Third Edition Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 30 (6) 495–553.CrossRefGoogle ScholarPubMed
Gray, R, Leese, M, Bindman, J, Becker, T, Burti, L, David, A, et al. (2006) Adherence Therapy for People with Schizophrenia: European Multicentre Randomised Controlled Trial. British Journal of Psychiatry 189 (6) 508–14.CrossRefGoogle ScholarPubMed
Haddad, PM and Wieck, A (2004) Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management. Drugs 64 (20) 2291–314.CrossRefGoogle ScholarPubMed
Hartley, M Haste, J and Sethi, F (2019) Non-Conventional Pharmacological Formulations for Enhancing the Management of Acute Disturbance. Journal of Psychiatric Intensive Care 15 (2) 79–86.CrossRefGoogle Scholar
Hirsch, SR, Link, CGG and Goldstein, JM (1996) ICI204,636: A New atypical Antipsychotic Medication. British Journal of Psychiatry 168 (Suppl 29]) 45–56.CrossRefGoogle Scholar
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, Krause, M, Samara, M, Peter, N, et al. (2019)Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults with Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. Lancet 394 (10202) 939–51.CrossRefGoogle ScholarPubMed
Hunt, C, Issakidis, C and Andrews, G (2002) DSM-IV Generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychological Medicine 32 (4) 649–59.CrossRefGoogle ScholarPubMed
Janssen-Cilag (2018a) Summary of Product Characteristics – Xeplion 100 mg Prolonged Release Suspension for Injection (Paliperidone). High Wycombe: Janssen-Cilag Ltd. www.medicines.org.uk/emc/product/7653/smpc.Google Scholar
Janssen-Cilag (2018b)Summary of Product Characteristics – Rispercal Consta 25 mg Powder and Solvent for Prolonged-Release Suspension for Injection (Risperidone). High Wycombe: Janssen-Cilag Ltd. www.medicines.org.uk/emc/product/1690/smpc.Google Scholar
Janssen-Cilag (2019) Summary of Product Characteristics – Trevicta 175 mg Prolonged Release Suspension for Injection (Paliperidone). High Wycombe: Janssen-Cilag Ltd. www.medicines.org.uk/emc/product/7230/smpc.Google Scholar
Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. (2006) A Randomized Controlled Trial of Effect on Quality of Life of Second Generation Versus First Generation Antipsychotic Drugs in Schizophrenia. Archives of General Psychiatry 63 (10) 1079–87.CrossRefGoogle Scholar
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al. (2008) Effectiveness of Antipsychotic Drugs in First Episode Schizophrenia and Schizophreniform Disorder: An Open Randomized Clinical Trial. Lancet 371 (9618) 1085–97.CrossRefGoogle Scholar
Kane, J, Canas, F, Kramer, M, Ford, L, Gassamann-Mayer, C, Lim, P, et al. (2006) Treatment of Schizophrenia with Paliperidone Extended-Release Tablets: A 6-Week Placebo-Controlled Trial. Schizophrenia Research 90 (1–3) 147–61.Google ScholarPubMed
Kane, J, Honigfield, G, Singer, J and Meltzer, HY (1988) The Lozaril Collaboration Study Group. Clozapine for the Treatment-Resistant Schizophrenic: A Double-Blind Comparison with Chlorpromazine. Archives of General Psychiatry 45 (9) 789–96.CrossRefGoogle Scholar
Kapur, S and Remington, G (2000) Atypical Antipsychotics: Patients Value the Lower Incidence of Extrapyramidal Adverse Effects. British Medical Journal 321 (7273) 1360–1.CrossRefGoogle Scholar
Kishimoto, T, Hagi, K, Nitta, M, Leucht, S, Olfson, M, Kane, JM, et al. (2018) Effectiveness of Long-Acting Injectable vs. Oral Antipsychotics in Patients with Schizophrenia: A Meta-Analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin 44 (3) 603–19.CrossRefGoogle ScholarPubMed
Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, et al. (2009a) A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. American Journal of Psychiatry 166 (2) 152–63.CrossRefGoogle ScholarPubMed
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C and Davis, JM (2009b) Second-Generation Versus First-Generation Antipsychotic Drugs for Schizophrenia: A Meta-Analysis. Lancet 373 (9697) 31–41.CrossRefGoogle ScholarPubMed
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. (2012) Antipsychotic Drugs Versus Placebo for Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis. Lancet 379 (9831) 2063–71.CrossRefGoogle ScholarPubMed
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, et al. (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple Treatments Meta-Analysis. Lancet 382 (9896) 951–62.CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine 353 (12) 1209–23.CrossRefGoogle ScholarPubMed
Llorca, P-M, Abbar, M, Courtet, P, Guillaume, S, Lancrenon, S and Samalin, L (2013) Guidelines for the Use and Management of Long-Acting Injectable Antipsychotics in Serious Mental Illness. BMC Psychiatry 13 (1) 340.CrossRefGoogle ScholarPubMed
Loebel, A, Cucchiaro, J, Xu, J, Sarma, K, Pikalov, A and Kane, J (2013a) Effectiveness of Lurasidone vs. Quetiapine XR for Relapse Prevention in Schizophrenia: A 12-Month, Double-Blind, Noninferiority Study. Schizophrenia Research 147 (1) 95–102.CrossRefGoogle ScholarPubMed
Loebel, A, Cucchiaro, J, Sarma, K, Xu, J, Hsu, C, Kalali, AH, et al. (2013b) Efficacy and Safety of Lurasidone 80 mg/day and 160 mg/day in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. Schizophrenia Research 145 (1–3) 101–9.CrossRefGoogle ScholarPubMed
Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Hsu, J, Sarma, K, et al. (2014a) Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry 171 (2) 160–8.Google ScholarPubMed
Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Sarma, K, Xu, J, et al. (2014b) Lurasidone as Adjunctive Therapy with Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry 171 (2) 169–77.Google ScholarPubMed
Loo, H, Poirer-Littre, MF, Theron, M and Fleurot, O (1997) Amisulpride versus Placebo in the Medium-Term Treatment of Negative Symptoms of Schizophrenia. British Journal of Psychiatry 170 (1) 18–22.CrossRefGoogle ScholarPubMed
Marder, SR and Meibach, RC (1994) Risperidone in the Treatment of Schizophrenia. American Journal of Psychiatry 151 (6) 825–35.Google ScholarPubMed
Markowitz, JS, Candace, SB and Moore, TR (1999) Atypical Antipsychotics: Pharmacology, Pharmacokinetics, and Efficacy. Annals of Pharmacotherapy 33 (1) 73–85.CrossRefGoogle ScholarPubMed
Medicines and Healthcare Products Regulatory Agency (MHRA)(2017) Clozapine: Reminder of Potentially Fatal Risk of Intestinal Obstruction, Faecal Impaction, and Paralytic Ileus. www.gov.uk/drug-safety-update/clozapine-reminder-of-potentially-fatal-risk-of-intestinal-obstruction-faecal-impaction-and-paralytic-ileus.Google Scholar
Medicines and Healthcare Products Regulatory Agency (MHRA) (2018) Valproate Use by Women and Girls: Information About the Risks of Taking Valproate Medicines During Pregnancy. www.gov.uk/guidance/valproate-use-by-women-and-girls.Google Scholar
Meltzer, HY, Cucchiaro, J, Silva, R, Ogasa, M, Phillips, D, Xu, J, et al. (2011) Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. American Journal of Psychiatry 168 (9) 957–67.CrossRefGoogle ScholarPubMed
Mortimer, A (1997) Treatment of the Patient with Long-Term Schizophreni. Advances in Psychiatric Treatment 3: 339–46.CrossRefGoogle Scholar
Muralidharan, K, Ali, M, Silveira, LE, Bond, DJ, Fountoulakis, KN, Lam, RW, et al. (2013) Efficacy of Second-Generation Antipsychotics in Treating Acute Mixed Episodes in Bipolar Disorder: A Meta-Analysis of Placebo-Controlled Trials. Journal of Affective Disorders 150 (2) 408–14.CrossRefGoogle ScholarPubMed
National Association of Psychiatric Intensive Care and Low Secure Units (NAPICU) (2014) National Minimum Standards for Psychiatric Intensive Care in General Adult Services. Glasgow: NAPICU.Google Scholar
National Association of Psychiatric Intensive Care and Low Secure Units (NAPICU) (2020) Managing Acute Disturbance in the Context of COVID-19. Glasgow: NAPICU.Google Scholar
National Institute for Health and Care Excellence (NICE) (2009a) Borderline Personality Disorder: Recognition and Management. Clinical Guideline [CG78]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2009b) Depression in Adults: The Treatment and Management of Depression in Adults. Clinical Guideline [CG90]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2011) Generalised Anxiety Disorder and Panic Disorder in Adults: Management. Clinical Guideline [CG113]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014a) Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance. NICE Clinical Guideline [CG192]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014b) Bipolar Disorder: Assessment and Management. NICE Clinical Guideline [CG185]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014c) Psychosis and Schizophrenia in Adults: Prevention and Management. Clinical Guideline [CG178]. London: NICE.Google Scholar
National Institute for Health and Care Excellence (NICE) (2015) Violence and Aggression: Short-Term Management in Mental Health, Health and Community Settings. NICE Guideline [NG10]. London: NICE. www.nice.org.uk/guidance/NG10.Google Scholar
Nose, M, Barbui, C and Tansella, M (2003) How Often Do Patients with Psychosis Fail to Adhere to Treatment Programmes? A Systematic Review. Psychological Medicine 33: 1149–60.CrossRefGoogle ScholarPubMed
Nutt, DJ and Blier, P (2016) Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology. Journal of Psychopharmacology 30 (5) 413–15.CrossRefGoogle ScholarPubMed
Organon Pharma (2021) Summary of Product Characteristics – Sycrest 10 mg Sublingual Tablets (Asenapine). London: Organon Pharma (UK) Limited. www.medicines.org.uk/emc/product/7737/smpc.Google Scholar
Ostrom, M, Eriksson, A, Thorson, J and Spigset, O (1996) Fatal Overdose with Citalopram. Lancet 348 (9023) 339–40.CrossRefGoogle ScholarPubMed
Otsuka (2020) Summary of Product Characteristics for Abilify Maintena 400 mg Powder and Solvent for Prolonged-Release Suspension (Aripiprazole) Clozapine. Wexham: Otsuka Pharmaceutics (UK) Ltd.Google Scholar
Paris, J (2000) Chronic Suicidality Among Patients with Borderline Personality Disorder. Psychiatric Services 53 (6) 738–42.Google Scholar
Patel, MX, Sethi, FN, Barnes, TR, Dix, R, Dratcu, L, Fox, B, et al. (2018) Joint BAP NAPICU Evidence-Based Consensus Guidelines for the Clinical Management of Acute Disturbance: De-Escalation and Rapid Tranquillisation. Journal of Psychopharmacology 32 (6) 601–40.CrossRefGoogle ScholarPubMed
Paton, C (2002) Benzodiazepines and Disinhibition: A Review. Psychiatric Bulletin 26 (12) 460–2.CrossRefGoogle Scholar
Paton, C and Okocha, CI (2004) Risperidone Long-Acting Injection: The First 50 Patients. Psychiatric Bulletin 28 (1) 12–14.CrossRefGoogle Scholar
Paton, C and Okocha, CI (2005) Pharmacological Treatment of Borderline Personality Disorder. Journal of Psychiatric Intensive Care Psychiatry 1 (2) 105–16.Google Scholar
Perry, PJ, Miller, DD, Arndt, SV and Cadoret, RJ (1991) Clozapine and Norclozapine Plasma Concentrations and Clinical Response of Treatment-Refractory Schizophrenic Patients. American Journal of Psychiatry 148 (10) 231–5.Google ScholarPubMed
Pope, HG, McElroy, SL, Keck, P and Hudson, JI (1991) Valproate in the Treatment of Acute Mania: A Placebo-Controlled Study. Archives of General Psychiatry 48 (1) 62–8.CrossRefGoogle Scholar
Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. (1999) Predictors of Relapse Following Response from a First Episode of Schizophrenia or Schizoaffective Disorder. Archives of General Psychiatry 56 (3) 241–7.CrossRefGoogle ScholarPubMed
Royal College of Physicians (2017) National Early Warning Score (NEWS) 2. London: Royal College of Physicians. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2.Google Scholar
Royal College of Psychiatrists (2014) Consensus Statement on High-dose Antipsychotic Medication, CR190. London: Royal College of Psychiatrists. www.rcpsych.ac.uk/files/pdfversion/CR190.pdf.Google Scholar
Royal College of Psychiatrists Psychopharmacology Committee (2017) Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice, 2nd ed. London: Royal College of Psychiatrists.Google Scholar
Srisurapanont, M, Sirijit, S, Maneeton, N and Maneeton, B (2015) Efficacy and Safety of Aripiprazole Augmentation of Clozapine in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Psychiatric Research 62: 38–47.CrossRefGoogle ScholarPubMed
Taylor, D, Barnes, TRE and Young, AH (2018) (eds.) The Maudsley Prescribing Guidelines in Psychiatry, 13th ed. Chichester: Wiley Blackwell.Google Scholar
Taylor, D and Duncan, D (1995) The Use of Clozapine Plasma Levels in Optimizing Therapy. Psychiatric Bulletin 19: 753–5.CrossRefGoogle Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, Mehtala, J, Hoti, F, Jedenius, E, et al. (2017) Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients with Schizophrenia. JAMA Psychiatry 74 (7) 686–93.CrossRefGoogle Scholar
Tollefson, GD, Beasley Jr, CM, Tran, PV, Street, JS, Krueger, JA, Tamura, RN, et al. (1997) Olanzapine Versus Haloperidol in the Treatment of Schizophrenia, Schizoaffective, and Schizophreniform Disorders: Results of an International Collaborative Trial. American Journal of Psychiatry 154 (4) 457–65.Google ScholarPubMed
Vieta, E, Reinares, M, Corbella, B, Benabarre, A, Gilaberte, I, Colom, F. et al. (2001) Olanzapine as Long-Term Adjunctive Therapy in Treatment-Resistant Bipolar Disorder. Journal of Clinical Psychopharmacology 21 (5) 469–73.CrossRefGoogle ScholarPubMed
Waddell, L and Taylor, M (2008) A New Self-Rating Scale for Detecting Atypical or Second-Generation Antipsychotic Side Effects. Journal of Psychopharmacology 22 (3) 238–43.CrossRefGoogle ScholarPubMed
Wilson, WH and Claussen, AM (1994) Seizures Associated with Clozapine Treatment in a State Hospital. Journal of Clinical Psychiatry 55 (5) 184–8.Google ScholarPubMed
Winston, AP (2000) Recent Developments in Borderline Personality Disorder. Advances in Psychiatric Treatment 6 (3) 211–8.CrossRefGoogle Scholar
Yildiz, A, Vieta, E, Leucht, S and Baldessarini, RJ (2011) Efficacy of Antimanic Treatments: Meta-Analysis of Randomized, Controlled Trials. Neuropsychopharmacology 36(2): 375–89.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×